Follow
Olivier Marcy
Olivier Marcy
Directeur de Recherche, IRD
Verified email at ird.fr
Title
Cited by
Cited by
Year
Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis
FX Blanc, T Sok, D Laureillard, L Borand, C Rekacewicz, E Nerrienet, ...
New England Journal of Medicine 365 (16), 1471-1481, 2011
8442011
Abortion care guideline
World Health Organization
World Health Organization, 2022
249*2022
AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d’Ivoire
X Anglaret, A Minga, D Gabillard, T Ouassa, E Messou, B Morris, M Traore, ...
Clinical infectious diseases 54 (5), 714-723, 2012
1282012
Performance of Xpert MTB/RIF and alternative specimen collection methods for the diagnosis of tuberculosis in HIV-infected children
O Marcy, V Ung, S Goyet, L Borand, P Msellati, M Tejiokem, ...
Clinical infectious diseases 62 (9), 1161-1168, 2016
1062016
Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV …
FX Blanc, T Sok, D Laureillard, L Borand, C Rekacewicz, E Nerrienet, ...
XVIII International AIDS Conference, 18-23, 2010
1042010
Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial
D Laureillard, O Marcy, Y Madec, S Chea, S Chan, L Borand, ...
Aids 27 (16), 2577-2586, 2013
882013
Natural killer cell degranulation capacity predicts early onset of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients with tuberculosis
P Pean, E Nerrienet, Y Madec, L Borand, D Laureillard, M Fernandez, ...
Blood, The Journal of the American Society of Hematology 119 (14), 3315-3320, 2012
732012
Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial
O Marcy, D Laureillard, Y Madec, S Chan, C Mayaud, L Borand, N Prak, ...
Clinical infectious diseases 59 (3), 435-445, 2014
692014
Dependence of Efavirenz- and Rifampicin-Isoniazid–Based Antituberculosis Treatment Drug-Drug Interaction on CYP2B6 and NAT2 Genetic Polymorphisms …
J Bertrand, C Verstuyft, M Chou, L Borand, P Chea, KH Nay, FX Blanc, ...
The Journal of infectious diseases 209 (3), 399-408, 2014
662014
Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1–infected adults receiving antiretroviral therapy in Africa and Asia: Data From the ANRS …
D Gabillard, C Lewden, I Ndoye, R Moh, O Segeral, B Tonwe-Gold, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 62 (5), 555-561, 2013
622013
Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study
K Zürcher, M Ballif, L Fenner, S Borrell, PM Keller, J Gnokoro, O Marcy, ...
The Lancet Infectious diseases 19 (3), 298-307, 2019
572019
TB-IRIS, T-cell activation, and remodeling of the T-cell compartment in highly immunosuppressed HIV-infected patients with TB
V Haridas, P Pean, LD Jasenosky, Y Madec, D Laureillard, T Sok, S Sath, ...
Aids 29 (3), 263-273, 2015
452015
A treatment-decision score for HIV-infected children with suspected tuberculosis
O Marcy, L Borand, V Ung, P Msellati, M Tejiokem, KT Huu, V Do Chau, ...
Pediatrics 144 (3), 2019
412019
Prevalence of lung function impairment in cured pulmonary tuberculosis patients in Cotonou, Benin
AA Fiogbe, G Agodokpessi, JF Tessier, D Affolabi, DM Zannou, G Adé, ...
The International Journal of Tuberculosis and Lung Disease 23 (2), 195-202, 2019
362019
Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non …
N De Castro, O Marcy, C Chazallon, E Messou, S Eholié, JB N'takpe, ...
The Lancet Infectious Diseases 21 (6), 813-822, 2021
312021
Paediatric tuberculosis–new advances to close persistent gaps
BJ Marais, S Verkuijl, M Casenghi, R Triasih, AC Hesseling, ...
International Journal of Infectious Diseases 113, S63-S67, 2021
302021
Low prevalence of drug resistance transmitted virus in HIV Type 1-infected ARV-naive patients in Cambodia
J Nouhin, S Ngin, PR Martin, O Marcy, L Kruy, F Ariey, M Peeters, ...
AIDS research and human retroviruses 25 (5), 543-545, 2009
302009
Dyslipidemias and elevated cardiovascular risk on lopinavir-based antiretroviral therapy in Cambodia
S Limsreng, O Marcy, S Ly, V Ouk, H Chanroeurn, S Thavary, B Boroath, ...
PLoS One 11 (8), e0160306, 2016
272016
Mortality from drug-resistant tuberculosis in high-burden countries comparing routine drug susceptibility testing with whole-genome sequencing: a multicentre cohort study
K Zürcher, ML Reichmuth, M Ballif, C Loiseau, S Borrell, M Reinhard, ...
The Lancet Microbe 2 (7), e320-e330, 2021
252021
Mortality and its determinants in antiretroviral treatment-naive HIV-infected children with suspected tuberculosis: an observational cohort study
O Marcy, M Tejiokem, P Msellati, KT Huu, V Do Chau, DT Ngoc, B Nacro, ...
The Lancet HIV 5 (2), e87-e95, 2018
252018
The system can't perform the operation now. Try again later.
Articles 1–20